Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beracsurf versus Curosurf for respiratory distress syndrome in preterm infants
IRCT20180404039187N4Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Variation of FiO2, Frequency of surfactant administration and 4 more. Started Jul 2019; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20180404039187N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180404039187N4.